



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

11th February, 2015

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

We wish to inform you that the Board of Directors at their meeting held on today taken on record the following:

1. Unaudited Financial Results (Standalone and Consolidated) and Report of Segment wise Revenue, Results and Capital employed for the Quarter ended 31st December, 2014 as per Clause 41 of the Listing Agreement along with Limited Review Report by the Statutory Auditors. Please find enclosed a copy of the same.
2. Dr.M.U.R.Naidu appointed as Additional Director of the Company.
3. Dr.D.Linga Rao, President (Technical Affairs) appointed as Additional Director of the Company who will be in the wholtime employment of the Company and be designated as Director & President (Technical Affairs).
4. The Board also recommended payment of an interim dividend of Rs.5/- per equity share of Rs.10/- each for the year 2014-2015.
5. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. record date is fixed for 25th February, 2015. The said interim dividend pay-by-date is 6th March, 2015.
6. The Board also took on record the acquisition of Natco Organics Limited promoters stake thereby Natco Organics Limited became 100% subsidiary.

Thanking you,

Yours faithfully,
for NATCO Pharma Limited

M Adinarayana
Company Secretary &
V.P. (Legal & Corporate Affairs)

Encl: as above.



Statement of stand-alone Financial Results for the quarter and nine months ended 31st December, 2014

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (REVIEWED)			YEAR-TO-DATE FIGURES (REVIEWED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC- 2014	30-SEP- 2014	31-DEC- 2013	31-DEC- 2014	31-DEC- 2013	
PART I : STATEMENT OF STAND-ALONE RESULTS						
01. Gross Sales / Income from Operations	16093	18677	16227	51720	44083	58960
Less : Excise Duty	160	215	201	717	450	582
Less : Sales Tax	356	351	321	1115	868	1174
Net Sales / Income from Operations	15577	18111	15705	49888	42765	57204
02. Other Operating Income	1119	1017	1718	4084	4146	5029
03. TOTAL INCOME FROM OPERATIONS	16696	19128	17423	53972	46911	62233
04. EXPENDITURE						
a) Cost of materials consumed	4881	3820	4485	12593	12111	16670
b) Purchases of stock-in-trade	-	-	-	-	-	-
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-198	725	-908	1004	-1410	-1597
d) Employee benefits expense	2793	2909	2492	8417	6911	9422
e) Depreciation and amortization expense	1075	1023	686	3117	1983	2679
f) Other Expenses	4432	5586	5531	15026	14304	19080
TOTAL EXPENSES	12983	14063	12286	40157	33899	46254
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3713	5065	5137	13815	13012	15979
06. Other Income	712	300	105	1100	632	1571
07. Profit/(Loss)from ordinary activities before finance Cost and exceptional items	4425	5365	5242	14915	13644	17550
08. Finance costs	811	699	877	2146	2792	3405
09.Profit/(Loss) from ordinary activities after finance Costs but before exceptional items	3614	4666	4365	12769	10852	14145
10. Exceptional Items	1513	-	-	1513	-	-
11. Profit / (Loss) from ordinary activities before tax	2101	4666	4365	11256	10852	14145
12. Tax expense, including deferred tax	440	1186	1123	2475	2467	3126
13. Net Profit / Loss (-) from ordinary activities after tax	1661	3480	3242	8781	8385	11019
14.Extraordinary items (net of tax expenses)	-	-	-	-	-	-
15.Net Profit/(Loss)for the period	1661	3480	3242	8781	8385	11019
16 Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3323	3307	3307	3323	3307	3307
17. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						69983
18. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	5.02 5.02	10.52 10.52	10.14 10.14	26.54 26.54	26.55 26.55	34.49 34.49
Part II : Select Information						
19. Public Shareholding:						
a) Number of Shares	15,373,985	15,373,943	15,311,593	15,373,985	15,311,593	15,365,107
b) Percentage of Shareholding	46.26	46.48	46.30	46.26	46.30	46.46
20 Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered –						
b) Non – encumbered – No. of shares	17,860,864	17,699,131	17,761,481	17,860,864	17,761,481	17,707,967
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.74	53.52	53.70	53.74	53.70	53.54

Dated at Hyderabad, this, the 11th day of February, 2015
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2014

Pending as on 01-10-2014	Nil
Received during the quarter	74
Resolved during the quarter	74
Pending as on 31-12-2014	Nil



Statement of consolidated Financial Results for the quarter ended 31st December, 2014

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS						
PARTICULARS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR-TO-DATE FIGURES (UNREVIEWED/UNAUDITED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC-2014	30-SEP-2014	31-DEC-2013	31-DEC-2014	31-DEC-2013	31-MAR-2014
01. Gross Sales / Income from Operations	18986	21532	19260	60327	53275	70656
Less : Excise Duty	196	267	321	829	1035	630
Less : Sales Tax	363	359	321	1135	877	1182
Net Sales / Income from Operations	18427	20906	18618	58363	51363	68844
02. Other Operating Income	1119	1017	1718	4084	4146	5045
03. TOTAL INCOME FROM OPERATIONS	19546	21923	20336	62447	55509	73889
04. EXPENDITURE						
a) Cost of materials consumed	6503	5716	6699	18282	18457	16010
b) Purchases of stock-in-trade	-	-	-	-	-	8889
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-198	725	-908	1004	-1410	-1577
d) Employee benefits expense	3329	3369	2976	9854	8198	11277
e) Depreciation and amortization expense	1218	1115	770	3446	2248	3045
f) Other Expenses	5156	6230	6177	16916	16056	21356
TOTAL EXPENSES	16008	17153	15714	49502	43549	59000
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3538	4770	4622	12945	11960	14889
06. Other Income	734	319	127	1171	675	1671
07. Finance costs	851	724	922	2231	2920	3662
8.Profit/(Loss) from ordinary activities after finance Costs but before exceptional items	3421	4365	3827	11885	9715	12898
09. Exceptional Item	1513	-	-	1513	-	-
10. Profit / (Loss) from ordinary activities before tax	1908	4365	3827	10372	9715	12898
11. Tax expense, including deferred tax	542	1241	1082	2661	2453	3087
12. Minority Interest	-68	-113	-243	-306	-610	-463
13. Net Profit / Loss (-) from ordinary activities after tax	1434	3237	2988	8017	7872	10274
14. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3323	3307	3307	3323	3307	3307
15. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						69280
16. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	4.33 4.33	9.79 9.79	9.34 9.34	24.23 24.23	24.94 24.94	32.16 32.16
17. Public Shareholding:						
a) Number of Shares	15,373,985	15,373,943	15,311,593	15,373,985	15,311,593	15,365,107
b) Percentage of Shareholding	46.26	46.48	46.30	46.26	46.30	46.46
18. Promoters and Promoter Group Shareholding	-	-	-	-	-	-
a) Pledged / Encumbered – No. of shares						
b) Non – encumbered – No. of shares	17,860,864	17,699,131	17,761,481	17,860,864	17,761,481	1,77,07,967
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.74	53.52	53.70	53.74	53.70	53.54

The stand-alone results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs. 5/- per equity share, payable on 6th March, 2015.

Dated at Hyderabad, this, the 11th February, 2015.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2014

Pending as on 01-10-2014	Nil
Received during the quarter	74
Resolved during the quarter	74
Pending as on 31-12-2014	Nil



Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and nine months ended on 31st December, 2014

Rs. lakhs

	THREE MONTHS ENDED REVIEWED			NINE MONTHS ENDED REVIEWED		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	31-DEC-2014	30-SEP-2014	31-DEC-2013	31-DEC-2014	31-DEC-2013	31-MAR-2014
01. Segment Revenue (Net)						
a) Bulk Chemicals	6339	7431	5827	22297	17757	22101
b) Formulations	9733	11882	11667	30581	27771	38702
c) Job Work	176	206	343	612	956	1193
d) Unallocated	788	240	230	1998	2123	2386
Total	17036	19759	18067	55488	48607	64382
Less : Inter-segment Revenue	340	631	644	1516	1696	2149
Net Sales / Income from Operations	16696	19128	17423	53972	46911	62233
02. Segment Results : Profit (+)/Loss (-) before tax and interest						
a) Bulk Chemicals	732	761	1509	5450	4077	4581
b) Formulations	3978	6579	5298	13625	11958	16857
c) Job Work	144	178	311	505	782	984
d) Unallocated	587	41	204	681	1912	2109
Total	5441	7559	7322	20261	18729	24531
Less : a) Interest	811	699	877	2146	2792	3405
b) Other unallocable expenditure	3241	2494	2185	7959	5717	8552
c) Unallocable income	(712)	(300)	(105)	(1100)	(632)	(1571)
Total Profit Before Tax	2101	4666	4365	11256	10852	14145
03. Capital Employed (Segment Assets – Segment Liabilities)						
a) Bulk Chemicals	49038	46920	40010	49038	40010	39578
b) Formulations	38056	40074	36689	38056	36689	38238
c) Job Work	188	173	236	188	236	165
e) Unallocated (Others)	-3687	-7170	-3940	-3687	-3940	-4691
Total	83595	79997	72995	83595	72995	73290

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 11th February, 2015. In accordance with the requirements to Schedule II of the Companies Act, 2013, the Company has re-assessed the useful life and residual value of the fixed assets and (i) An amount of ₹411 lakhs (net of deferred tax charge of ₹212 lakhs) has been charged to the opening balance of the retained earnings in respect of assets whose remaining useful life is nil as at 1 April 2014, ii) The profit for the quarters ended 31 December 2014, 30 September 2014 and nine months ended 31 December 2014 has decreased by ₹334 lakhs, ₹299 lakhs and ₹939 lakhs respectively on account of application of Schedule II. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Exceptional item represents amount paid and accounted against settlement pending legal dispute Rs.1513/-lakhs. The results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs.5/- per equity share, (Rs.5/-per equity share during nine months ended 31st December, 2013) payable on 6th March, 2015. During the quarter, the company had acquired the promoters stake in NATCO Organics Limited for consideration other than cash and allotted 1,61,775 equity shares of NATCO Pharma Limited Rs. 10/- each, at a premium of Rs.1190/- per share.

Dated at Hyderabad, this, the 11th day of February, 2015
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
(Formerly Walker, Chandiok & Co)
7th Floor, Block III, White House
Kundan Bagh, Begumpet
Hyderabad 500016
India

T +91 40 6630 8200
F +91 40 6630 8230

Review Report

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of NATCO Pharma Limited ("the Company") for the quarter ended 31 December 2014 and the year to date results for the period 1 April 2014 to 31 December 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. *The Company has not recognized Minimum Alternative Tax (MAT) credit entitlement pertaining to the period 1 April 2009 to 31 December 2014, as required by the Guidance Note on "Accounting for Credit available in respect of Minimum Alternative Tax under the Income Tax Act, 1961", issued by the Institute of Chartered Accountants of India. Had the Company accounted for such MAT credit, the net profit after tax for the quarter and nine month period ended 31 December 2014 would have been higher by ₹9127 lakhs (₹7,371 lakhs and ₹8,614 lakhs and ₹8,817 for the quarter and nine month period ended 31 December 2013; quarter ended 30 September 2014; and year ended 31 March 2014, respectively). This matter had caused us to qualify our review reports and audit report for all the presented comparative periods.*



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurgaon, Hyderabad, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Walker Chandiok & Co LLP

4. Based on our review conducted as above, *except for the effects of qualification as described in the previous paragraph*, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We have neither performed a review nor performed an audit of the figures/notes for the consolidated financial results for the quarter ended 31 December 2014, 30 September 2014 and 31 December 2013 and year to date results for the period ended 31 December 2014 and 31 December 2013 as reported in the statement and accordingly do not express any opinion thereon.

Walker Chandiok & Co LLP
For Walker Chandiok & Co LLP

(formerly Walker, Chandiok & Co)

Chartered Accountants

Firm Registration No: 001076N/N500013

Sanjay Kumar Jain
per Sanjay Kumar Jain
Partner

Membership No. 207660

Place : Hyderabad

Date : 11 February 2015

